Trial Profile

A Phase II Study of Itacitinib in Patients With Steroid Refractory Immune Related Adverse Events Arising From Immune Checkpoint Inhibitors

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 04 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Corticosteroid (Primary) ; Corticosteroid (Primary) ; Itacitinib (Primary)
Indications Cancer
Focus Adverse reactions

Most Recent Events

31 Oct 2024 Planned primary completion date changed from 30 Apr 2026 to 30 Sep 2026.
31 Oct 2024 Planned initiation date changed from 30 Sep 2024 to 30 Jan 2025.
31 Oct 2024 Status changed from not yet recruiting to withdrawn prior to enrolment.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com